EPIX Projected Dividend Yield
ESSA Pharma Inc ( NASDAQ : EPIX )ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. Co. is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, Masofaniten (formerly EPI-7386), is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). Masofaniten is in development in combination with antiandrogen treatments in patients with prostate cancer who are earlier in their course of the disease. Co. is completing the clinical development of masofaniten as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). 21 YEAR PERFORMANCE RESULTS |
EPIX Dividend History Detail EPIX Dividend News EPIX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |